Christine Rouzioux
Overview
Explore the profile of Christine Rouzioux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
279
Citations
9101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vemparala B, Madelain V, Passaes C, Millet A, Avettand-Fenoel V, Djidjou-Demasse R, et al.
PLoS Comput Biol
. 2024 Sep;
20(9):e1012434.
PMID: 39255323
While most individuals suffer progressive disease following HIV infection, a small fraction spontaneously controls the infection. Although CD8 T-cells have been implicated in this natural control, their mechanistic roles are...
2.
Passaes C, Desjardins D, Chapel A, Monceaux V, Lemaitre J, Melard A, et al.
Nat Commun
. 2024 Jan;
15(1):178.
PMID: 38212337
HIV remission can be achieved in some people, called post-treatment HIV controllers, after antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was suggested to favor post-treatment control,...
3.
4.
Tremeaux P, Lemoine F, Melard A, Gousset M, Boufassa F, Orr S, et al.
Microbiol Spectr
. 2023 Jan;
11(1):e0326722.
PMID: 36692300
In the search for control of human immunodeficiency virus type 1 (HIV-1) infection without antiretroviral therapy, posttreatment controllers (PTCs) are models of HIV remission. To better understand their mechanisms of...
5.
Breton G, Cisse M, Diallo O, Diallo N, Soumaoro S, Camara Y, et al.
J Antimicrob Chemother
. 2022 Aug;
77(11):3093-3101.
PMID: 36031792
Background: Nearly half of HIV-infected children worldwide are born in West and Central African countries where access to prevention of mother-to-child transmission of HIV (PMTCT) programmes is still limited. WHO...
6.
Cheret A, Bauer R, Meiffredy V, Lopez P, Ajana F, Lacombe K, et al.
J Antimicrob Chemother
. 2022 Jun;
77(9):2506-2515.
PMID: 35762503
Background: Whether integrase strand transfer inhibitors (INSTIs) can decrease HIV-1 DNA levels more rapidly than boosted PIs during primary HIV-1 infection (PHI) is unknown. We hypothesized that once-daily dolutegravir/tenofovir/emtricitabine could...
7.
Verdikt R, Bendoumou M, Bouchat S, Nestola L, Pasternak A, Darcis G, et al.
EBioMedicine
. 2022 Apr;
79:103985.
PMID: 35429693
Background: The multiplicity, heterogeneity, and dynamic nature of human immunodeficiency virus type-1 (HIV-1) latency mechanisms are reflected in the current lack of functional cure for HIV-1. Accordingly, all classes of...
8.
Molinos-Albert L, Lorin V, Monceaux V, Orr S, Essat A, Dufloo J, et al.
Nat Commun
. 2022 Apr;
13(1):1944.
PMID: 35410989
HIV-1 post-treatment controllers are rare individuals controlling HIV-1 infection for years after antiretroviral therapy interruption. Identification of immune correlates of control in post-treatment controllers could aid in designing effective HIV-1...
9.
Mariaggi A, Bauer R, Charre C, Gardiennet E, Meiffredy V, Ajana F, et al.
J Antimicrob Chemother
. 2022 Feb;
77(3):735-739.
PMID: 35195692
Background: Dolutegravir is a widespread integrase strand-transfer inhibitor (INSTI) recommended for treatment of primary HIV infection (PHI). PHI is a high-risk stage for sexual transmission because of the high viral...
10.
Ntakpe J, Gabillard D, Moh R, Gardiennet E, Toni T, Kouame G, et al.
AIDS
. 2021 Sep;
36(1):29-38.
PMID: 34524145
Background: Data on HIV-1 controllers in Africa are scarce. We report the proportion of HIV-1 controllers in a group of adults prospectively monitored with frequent viral load measurements as part...